**Supplementary Table 3. Subject disposition for annual resistance surveillance at weeks 48, 96, and 144 (pooled results for Studies GS-US-320-0108 and GS-US-320-0110)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Week 48\*** | **Week 96** | **Week 144** |
| **Category (n)** | **TAF**  | **TDF**  | **All**  | **TAF** | **TDF** | **All** | **TAF** | **TDF** | **All** |
| Patients with HBV DNA ≥69 IU/mL | 46 | 13 | 59 | 16 | 7 | 23 | 9 | 5 | 14 |
| Patients qualified for sequencing | 6 | 1 | 7 | 16 | 7 | 23 | 9 | 5 | 14 |
|  Unable to sequence | 3 | 0 | 3 | 4 | 1 | 5 | 4 | 2 | 6 |
|  No change from baseline | 1 | 0 | 1 | 7 | 1 | 8 | 4 | 1 | 5 |
|  Polymorphic site substitution | 2 | 1 | 3 | 5 | 1 | 6 | 1 | 0 | 1 |
|  Conserved site substitution | 0 | 0 | 0 | 0 | 4 | 4 | 0 | 2 | 2 |
| Patients qualified for phenotyping | 1 | 0 | 1 | 4 | 4 | 8 | 1 | 2 | 3 |

TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate
\*Only patients with virologic breakthrough (confirmed HBV DNA ≥69 IU/mL after achieving <69 IU/mL, or >1 log10 IU/mL increase in HBV DNA from nadir) were tested for resistance at week 48. At weeks 96 and 144 patients with persistent viremia and viral blips were sequenced in addition to virologic breakthrough.